Tevogen Bio Holdings
TVGN
30 hedge funds and large institutions have $614K invested in Tevogen Bio Holdings in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 27 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
3.32% more ownership
Funds ownership: 0.05% → 3.37% (+3.3%)
41% less funds holding
Funds holding: 51 → 30 (-21)
63% less capital invested
Capital invested by funds: $1.68M → $614K (-$1.07M)
74% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$151K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$145K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$99.5K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$70.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$57.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$90.6K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$64.6K |
| 3 |
State Street
Boston,
Massachusetts
|
-$44K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$29.9K |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
-$29.9K |
TVGN Hedge Fund Activity: Q1 2026 in Review
30 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Tevogen Bio Holdings (TVGN) for Q1 2026, worth a combined $614K — down 63% from $1.68M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of TVGN and 7 opened new positions — a net loss of 20 holders — while 7 trimmed existing stakes and 13 added.
The largest buyer was Morgan Stanley, adding an estimated $151K. The largest seller was Goldman Sachs, exiting entirely with an estimated $90.6K sold.
- 30 institutional investors held Tevogen Bio Holdings (TVGN) as of Q1 2026, down from 51 in Q4 2025.
- Funds reported $614K of Tevogen Bio Holdings stock for Q1 2026, down 63% quarter-over-quarter.
- 7 funds opened new Tevogen Bio Holdings positions in Q1 2026 and 27 closed out, a net change of -20 holders.
- The largest Tevogen Bio Holdings buyer in Q1 2026 was Morgan Stanley, an estimated $151K added.
- The largest Tevogen Bio Holdings seller in Q1 2026 was Goldman Sachs, an estimated $90.6K sold.
Based on aggregated 13F filings for Q1 2026.